RELMADA THERAPEUTICS, INC. — Director's Dealing 2025

Jul 1, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2025-06-26

Reporting Person: TRAVERSA SERGIO (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-26	Stock Option (right to buy)	$0.67	A	800000	Acquired	2035-06-26	Common Stock (800000)	Direct

Footnotes

F1: The options vest in 16 equal quarterly installments commencing on September 26, 2025.